Seer, Inc. (SEER), a biotechnology company specializing in proteomic research tools, demonstrates a permissible core business under Shariah principles but faces significant challenges from elevated liquidity and interest income ratios that exceed standard financial screening thresholds across major authorities. While debt levels remain compliant, the high cash holdings and interest-bearing income necessitate purification and raise concerns about riba exposure. Index inclusion research confirms exclusion from all major Shariah indices due to these financial metrics. Overall, the company is classified as non-compliant, though its innovative healthcare focus aligns with Islamic objectives of preserving life. Investors may consider monitoring for financial improvements or consulting scholars for purification-guided investment.